125 Nanoparticle Enhanced MRI-Guided Radiation Therapy: Final proof of concept before phase I trial.  by Kotb, S. et al.
ICTR-PHE 2016  S61 
 
1Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany 
2OncoRay – National Center for Radiation Research in 
Oncology, Dresden, Germany 
 
Purpose: At the OncoRay center in Dresden at proton 
therapy facility is in operation. The first patient was 
treated in December 2014. The system is driven by an 
IBA (IBA Proton Therapy, Louvain-la-Neuve, Belgium) 
Cyclone 230 isochronous cyclotron with a maximum 
proton energy of 230 MeV. Patients are treated in one 
room equipped with a 360° rotating gantry. Besides 
patient treatment a strong focus is on research. A 
dedicated experimental room is part of the facility. In the 
current state of expansion this room is equipped with a 
fixed beam line. Beam energies between 70 and 230 MeV 
and currents up to about 120 nA at 230 MeV can be 
provided. 
Materials and Methods: An in house developed control 
system (figure 1) allows for a parallel operation of the 
treatment and the experimental beamline. Absolute 
priority for the treatment room is ensured by the control 
software. 
The beam current is controlled by a dedicated 
hardware directly. Continuous wave beams as well as 
pulsed beams with repetition rates up to 333 Hz with 
variable duty cycles are available. The beam is 
monitored by means of a segmented ionization 
chamber. The beam can be activated manually, for a 
defined time or until a certain charge has been reached 
at the beam exit. A direct continuance after a beam switch 
to the treatment room is possible. 
Results: The proton therapy system itself is operated by 
an IBA team, that ensures excellent beam stability and 
availability. Since only one treatment room is present, 
experiments can be performed conveniently during the day 
shifts. Requests from the treatment room cause 
interruptions of 1-2 min duration in intervals of about 20 
min. 
Conclusions: In summary, the OncoRay center is equipped 
with an experimental beamline that combines the 
reliability and beam quality of a commercial clinical proton 
therapy system with the flexibility of an in house 
developed control system whose design parameters are 
governed by the needs of physical and translational 
research. 
 
 
Figure 1: A screenshot of the interface for the operator at 
the control room for the experimental area. 
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Purpose: Radiation therapy is currently prescribed to more 
than 60 % of cancer patients1. However, effective treatment 
is often limited by tumor visualization and collateral damage 
of healthy tissues. One possibility to overcome this problem, 
besides using a local approach such as stereotactic 
radiosurgery, is combining radiation with nanoparticles 
containing high-Z elements which are known to boost locally 
the efficacy of radiation exposure during cancer therapy. In 
this context, we developed gadolinium-based nanoparticles 
named AGuIX (Activation-Guided Irradiation by X-ray) for 
MRI-guided radiotherapy. 
Material and methods: (AGuIX) nanoparticles were obtained 
as previously described2. We performed in vitro 
radiosensitization clonogenic assay with 220kVp X-ray at 
doses ranging from 0 to 6 Gy on B16F10 mouse melanoma cell 
line, in addition to cell uptake characterization using TEM 
and confocal microscopy. In vivo, B16F10 mouse melanoma 
cells were orthotopically grafted into mouse brains to mimic 
human melanoma brain metastases. After intravenous 
injection of 10 µmol of (AGuIX) into mice bearing B16F10, MR 
and intravital two photon microscopy imaging were 
performed to determine the maximum tumor uptake, and 
tumor vs. healthy tissue ratio before radiation therapy. 
Similar to the clinical workflow, an image guided cone-beam 
CT (CBCT) was performed prior to irradiation exposure to 
calculate the delivered dose during whole brain radiotherapy 
(WBRT) to the brain, the metastases and other organs at risk. 
Results: Radiosensitization shows a significant effect (P<0.05) 
when the (AGuIX) are combined with 220 kVp X-rays exposure 
in vitro. The percentage enhancement factor at 2 Gy (%EF 2 
Gy) was 60 % compared with that for radiation alone, with a 
significant increase in DNA double strand breaks (P<0.01). In 
vivo the (AGuIX) nanoparticles accumulate passively in brain 
tumors; such phenomenon has previously been reported in 
brain-tumor bearing animals3. After radiation exposure, the 
increase in life spans (ILS) compared to control group was 
8.3% for the animals that were only irradiated and increased 
to 25% with pre-injection of (AGuIX) nanoparticles; such 
increase corresponds to 15.4% compared to irradiated 
animals (P=0.0025). Histological observation of the brains 
indicated the presence of large metastases for the control 
and irradiated only group compared to the group treated by 
the combination of irradiation with nanoparticles4,5.  
Conclusion: (AGuIX) nanoparticles are not only potential 
radiosensitizing agent, but it also acts as positive contrast 
agent for MRI, which allows accurate delineation of the 
tumor region instead of using conventional CT. Regulatory 
toxicity investigations demonstrated the absence of any side 
effects, even at repeated injections. A clinical trial phase I 
on patients with multiple brain metastases will be launched 
in France winter 2016. 
                      
 
Fig. 1. Guided and enhanced radiotherapy with (AGuIX) 
nanoparticles. 
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Outcome of radiation therapy depends on accurate, robust 
and verified calculations of the planned dose. Monte Carlo 
(MC) is considered as the gold standard for dosimetric 
calculations, however its popularity in a clinical environment 
is still limited. One of the reasons is the typically complex 
procedure of setting the patient models and beam 
parameters. The focus of physical models development in the 
FLUKA [1][2] MC code, since many years, is put on the 
medical area, making it an ideal tool applicable for the 
nuclear medicine and hadron-therapy simulations. It is 
already used in the clinical environment in HIT and CNAO for 
generating Treatment Planning System (TPS) databases and 
offline treatment verification. The aim of this work is to 
present the recent improvements of FLUKA and its Graphical 
User Interface - Flair [3] providing a fully-functional and 
easy-to-use tool for quality assurance (QA) of treatment 
plans for protons, carbon and other light ion species. 
In this study we present the most recent developments, 
based on several re-calculations of complete proton/ion 
treatment plans from different TPS and facilities using Flair 
and FLUKA. FLUKA recently was enhanced with the RBE 
estimator and dedicated PET, prompt-gamma and charged 
particles scoring for beam range verification. To better 
utilize these advantages, Flair facilitates the application of 
the treatment scheme into the simulation procedure. It is 
able to import the CT DICOM images creating the voxel-
phantom geometries based on parameterization according to 
Schneider et al[4]. Flair allows importing the entire 
treatment scheme directly from the RT DICOM files, such as 
RTSTRUCT, RTDOSE and RTPLAN. To better comply with the 
real irradiation settings, Flair incorporates also the basis 
characteristics of the beam delivery system with the minimal 
effort from the user point of view. 
Several comparisons were made between the TPS and the 
FLUKA simulation scheme. The DVH plots for the PTV/OAR 
shows good agreement for the presented cases; some dose 
deposition differences in various tissues are noticeable, 
especially in the end of the ranges of the beam particles. 
FLUKA physical models were thoroughly validated, hence, 
quantification and identification of the discrepancies, 
especially taking into consideration more complex cases – like 
patients/organs with the more heterogeneous structures, 
may bring a great value for the treatment quality. 
Additional, independent re-calculation is always an asset, 
and usage of FLUKA and its efficient graphical user interface 
Flair, can enhance the popularity of the MC in the clinical 
environment for both research and QA purposes. 
The presented results will be used for further work on the 
tool development, assuring the quality of the treatment 
plans and providing the user with the guidelines for the 
treatment plan optimization. 
 
 
Fig: Flair screenshot of the comparison between TPS and 
FLUKA simulations 
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Purpose: We present an improved method to calculate 
patient-specific calibration curves to convert X-ray computed 
tomography (CT) Hounsfield Unit (HU) to relative stopping 
powers (RSP) for proton therapy treatment planning. We 
introduce also an optimization method to improve the spatial 
resolution and the water equivalent thickness (WET) accuracy 
of proton radiographies [1].  
Materials/Methods: By optimizing the HU-RSP calibration 
curve, the difference between a proton radiographic image 
and a digitally reconstructed X-ray radiography (DRR) is 
minimized. The feasibility of this approach has previously 
been demonstrated [2,3]. This scenario assumes that all 
discrepancies between proton radiography and DRR originate 
from uncertainties in the HU-RSP curve. In reality, external 
factors cause imperfections in the proton radiography, such 
as misalignment compared to the DRR and unfaithful 
representation of geometric structures (“blurring”). We 
